Stay updated with breaking news from Technology Incubation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study -- -- RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2...
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rally...
-- First-In-Human Single Ascending Dose Clinical Data for RLYB116 Demonstrated a Reduction in Free C5 Greater than 99% at 24 Hours for the 100 mg dose and at 12, 24, and 72 Hours for the 300 mg dose in Healthy Participants ---- Mean Estimated Elimination Half-Life for RLYB116 was > 300 Hours ---- No Severe or Seriou...
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...